Loading...
•
Oct 31, 2024
Avid Bioservices Q2 2025 Earnings Report
Delivered solid results with increased revenues and backlog offset by increased costs.
Key Takeaways
Avid Bioservices reported solid results for Q2 2025, marked by increased revenues and backlog, although these were offset by increased costs. The company also announced an agreement with GHO and Ampersand, expected to close in Q1 2025, providing stockholders with significant cash value.
Revenues increased in a competitive environment.
Backlog increased during the quarter.
Costs also increased during the quarter.
Agreement reached with GHO and Ampersand to provide stockholders with cash value.
Forward Guidance
In light of the proposed transaction with GHO Capital Partners and Ampersand Capital Partners, Avid Bioservices is suspending its practice of providing financial guidance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...